Infliximab as an Effective Second-Line Treatment for IVIG-Resistant Kawasaki Disease Accompanied by Severe Dyslipidemia - Takeaways - MDSpire

Infliximab as an Effective Second-Line Treatment for IVIG-Resistant Kawasaki Disease Accompanied by Severe Dyslipidemia

  • By

  • Yuto Sunaga

  • Yohei Hasebe

  • Masashi Yoshizawa

  • Yosuke Kono

  • Keiichi Koizumi

  • Nobuyuki Katsumata

  • Takako Toda

  • Minako Hoshiai

  • Koji Kobayashi

  • Sho Hokibara

  • Hiroko Oshiro

  • Emi Sawanobori

  • Tomoaki Sano

  • Masanori Ohta

  • Makoto Tsuruta

  • Makoto Nakamura

  • Kazumasa Sato

  • Hiroki Sato

  • Takeshi Inukai

  • June 4, 2026

  • 0 min

Share

  • 1

    Kawasaki disease primarily affects medium-sized arteries and can lead to serious complications like coronary artery abnormalities.

  • 2

    Approximately 20% of Kawasaki disease patients are resistant to initial IVIG treatment, necessitating effective second-line therapies.

  • 3

    Infliximab has shown superiority over additional IVIG in treating IVIG-resistant Kawasaki disease, with faster fever resolution.

  • 4

    A study analyzed 190 IVIG-resistant Kawasaki disease patients, identifying clinical subgroups for tailored second-line therapy.

  • 5

    Machine learning techniques were employed to cluster patients based on laboratory factors, aiding in treatment response prediction.

Original Source(s)

Infliximab as an Effective Second-Line Treatment for IVIG-Resistant Kawasaki Disease Accompanied by Severe Dyslipidemia

  • by Yuto Sunaga, Yohei Hasebe, Masashi Yoshizawa, Yosuke Kono, Keiichi Koizumi, Nobuyuki Katsumata, Takako Toda, Minako Hoshiai, Koji Kobayashi, Sho Hokibara, Hiroko Oshiro, Emi Sawanobori, Tomoaki Sano, Masanori Ohta, Makoto Tsuruta, Makoto Nakamura, Kazumasa Sato, Hiroki Sato, Takeshi Inukai

  • June 4, 2026

Related Content

Pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as prognostic biomarkers for neuroblastoma risk stratification

I’m a pediatrician. I want to prescribe the right AI to my patients

Radiation Reduction Through the Use of a Novel Ultra-Low Dose Fluoroscopy Imaging Protocol in Congenital Cardiac Catheterization